

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

POLL RESULT OF THE SPECIAL GENERAL MEETING HELD ON 2 SEPTEMBER 2021

The Board is pleased to announce that the Resolution as set out in the Notice was duly passed as an ordinary resolution of the Company by the Shareholders by way of poll at the SGM held on 2 September 2021.

Reference is made to the circular (“**Circular**”) and notice (“**Notice**”) of the special general meeting (“**SGM**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 12 August 2021. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the resolution as set out in the Notice (“**Resolution**”) was duly passed as an ordinary resolution of the Company by the Shareholders by way of poll at the SGM held on 2 September 2021.

As at the date of the SGM, the total number of the issued Shares was 1,671,846,657, which was the total number of Shares entitling the Shareholders to attend and vote on the Resolution at the SGM. There was no Share entitling any Shareholder to attend and abstain from voting in favour of the Resolution at the SGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting at the SGM and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the Resolution at the SGM.

The full text of the Resolution was set out in the Notice. The poll result was as follows:

ORDINARY RESOLUTION	Number of votes (%)	
	FOR	AGAINST
To approve, confirm and ratify the Share Repurchase Agreement and the transactions contemplated thereunder and to authorise any one of the directors of the Company to take all such actions as he/she considers necessary, appropriate, desirable and expedient for the purposes of giving effect to or in connection with the Share Repurchase Agreement and all transactions contemplated thereunder.	437,408,000 (100.00%)	0 (0.00%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the SGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of the Resolution, the Resolution was duly passed as an ordinary resolution of the Company by the Shareholders at the SGM.

The branch share registrar and transfer office of the Company in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the SGM.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 2 September 2021

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Note: Trading in the Shares has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the Securities and Futures Commission in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong). Trading in the Shares will remain suspended until further notice. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.